ロード中...
Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study
AIMS: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). MATERIALS AND METHODS: Eligible participants from INSTRIDE 1 who comple...
保存先:
| 出版年: | Diabetes Obes Metab |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7065063/ https://ncbi.nlm.nih.gov/pubmed/31691472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13904 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|